The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy

Annals of the Rheumatic Diseases

Volumn 68, Issue 9, 2009, Pages 1377-1380

  Matucci Cerinic, M ^a   Allanore, Y ^b   Czirjak L ^c   Tyndall, A ^d   Muller Ladner U ^e   Denton, C ^f   Valentini, G ^g   Distler, O ^h   Fligelstone, K ⁱ   Tyrrel Kennedy, A ⁱ   Farge, D ^j   Kowal Bielecka, O ^k   Van Den Hoogen, F ^l   Cutolo, M ^m   Sampaio Barros, P D ⁿ   Nash, P ^o   Takehara, K ^p   Furst, D E ^q  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF PÉCS   (Hungary)

^d UNIVERSITY OF BASEL   (Switzerland)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ Federation of the European Scleroderma Associations ^*

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^l SINT MAARTENSKLINIEK   (Netherlands)

^m UNIVERSITY OF GENOA   (Italy)

ⁿ UNIVERSITY OF CAMPINAS   (Brazil)

^o UNIVERSITY OF QUEENSLAND   (Australia)

^p KANAZAWA UNIVERSITY   (Japan)

^q UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CALCIUM CHANNEL BLOCKING AGENT; CENTROMERE ANTIBODY; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA TOPOISOMERASE ANTIBODY; ENDOTHELIN RECEPTOR ANTAGONIST; METHOTREXATE; PHOSPHODIESTERASE INHIBITOR; PROSTANOID; RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

CAPILLAROSCOPY; CLINICAL TRIAL; DELPHI STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; FINGER; HUMAN; MEDICAL RESEARCH; MYOSITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

EARLY DIAGNOSIS; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 69949135633     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.106302     Document Type: Review

References (30)

1. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Clement M, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10. (Pubitemid 40082450)
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-567 (Pubitemid 46348510)
3. Anonymous. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590
4. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-205 (Pubitemid 18073738)
5. Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001;44:735-736 (Pubitemid 32234635)
6. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-763 (Pubitemid 46846694)
7. Hudson M, Taillefer S, Steele R, Dunne J, Johnson SR, Jones N, et al. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007;25:754-757 (Pubitemid 350284851)
8. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-2444
9. Nagy Z, Czirjak L. Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud's disease. J Eur Acad Dermatol Venereol 2004;18:62-68 (Pubitemid 38165264)
10. Cutolo M, Grassi W, Matucci Cerinic M. Capillaroscopy and Raynaud's phenomenon. Arthritis Rheum 2003;46: 3023-3027
11. Fine LG, Denton CP, Korn J, de Crombrugghe B, Black CM. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapies. Lancet 1996;3,47:1453-1458 (Pubitemid 26161211)
12. LeRoy EC, Maricq HR, Kahaleh BM. Undifferentiated connective tissue syndromes. Arthritis Rheum 1980;23:341-343
13. Lundberg IE. The prognosis of MCTD. Rheum Dis Clin North Am 2005;31:535-547
14. Wigley FM. When is scleroderma really scleroderma? J Rheumatol 2001;28:1471-1473
15. Leroy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22:675-694
16. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-1576 (Pubitemid 32660630)
17. Hudson M, Thombs B, Baron M. Time to diagnosis in systemic sclerosis: is gender a factor? Arthritis Rheum 2007;56(suppl):S487.
18. Cutolo M, Matucci-Cerinic M. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007;25:663-665 (Pubitemid 350284837)
19. Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006;54:1974-1981 (Pubitemid 43877947)
20. Cutolo M, Pizzorni C, Sulli A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl, et al. Arthritis Rheum 2007;56:2102-2103
21. Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2003;21:313-320 (Pubitemid 36752614)
22. Williams HJ, Alarcon GS, Joks R, Steen VD, Bulpitt K, Clegg DO, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 1999;26:816-825 (Pubitemid 29195668)
23. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999;42:899-909.
24. Gendi NS, Welsh KI, Van Venrooij WJ, Vancheeswaran R, Gilroy J, Black CM. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic follow up of 46 patients. Arthritis Rheum 1995;38:259-266
25. Bodolay E, Szekanecz Z, Dévényi K, Galuska L, Csípo I, Vègh J, et al. Evaluation of interstitial lung disease in mixed connective tissue disease. Rheumatology (Oxford) 2005;44:656-661 (Pubitemid 41487239)
26. Bellando Randone S, Cutolo M, Czirjak L, Matucci Cerinic M. Mixed connective tissue disease, a roundabout to rheumatic diseases? Curr Rev Rheumatol (in press).
27. Grader-Beck T, Wigley FM. Raynaud's phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am 2005;31:465-481 (Pubitemid 41111549)
28. Ziegler S, Brunner M, Eigenbauer E, Minar E. Long-term outcome of primary Raynaud's phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. Scand J Rheumatol 2003;32:343-347 (Pubitemid 38177790)
29. Van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ten Wolde S, Han KH, van Krugten MV, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007;56:2129-2134 (Pubitemid 47173559)
30. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR/EUSTAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2009;68:620-628